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ENDOCRINE-DISRUPTING CHEMICALS: 
TESTING TO PROTECT FUTURE 
GENERATIONS 
Alana Van der Mude* 
Abstract: Endocrine-disrupting chemicals (EDCs) are chemicals that inter-
fere with human hormone processes. EDCs are omnipresent: pesticides, 
plastics, and drugs, among other common chemicals, all demonstrate en-
docrine-disrupting properties. Scientific studies have demonstrated the 
frightening effects EDCs have on human health, particularly for fetuses 
while they develop in utero. Given these health concerns, Congress passed 
the Food Quality Protection Act of 1996, which requires the EPA to test pes-
ticides for their endocrine-disrupting properties. Frustratingly this testing, 
fifteen years later, has still not begun. Therefore this Note argues that citi-
zens should bring suit under the Administrative Procedure Act to compel 
EPA to complete testing of pesticides for endocrine-disrupting properties, 
all with the goal of furthering effective regulation of EDCs. 
Introduction 
The ultimate success of this reform will rest with the professionalism and the 
common sense of the Environmental Protection Agency. Congress will be 
watching closely as we try to implement these reforms. We will, to ensure that 
science, not emotion, is the basis of pesticide regulation.1 
 
 The synthetic estrogen drug, DES, is one of many known endo-
crine-disrupting chemicals, and an infamous example of why these 
chemicals need to be tested and regulated.2 In the late 1960s, an un-
usual cluster of clear-cell adenocarcinoma—a rare form of vaginal can-
cer—appeared in Boston.3 Doctors were particularly concerned not 
only because clear-cell adenocarcinoma is an incredibly unusual form 
of cancer, but also because the women diagnosed were all under twen-
                                                                                                                      
* Editor in Chief, Boston College Environmental Affairs Law Review, 2010–11. 
1 142 Cong. Rec. 18,588 (1996).  
2 See Theo Colborn et al., Our Stolen Future: Are We Threatening Our Fertility, 
Intelligence, and Survival?—A Scientific Detective Story 67 (Plume 1997) (1996). 
3 Id. at 55. 
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ty-two years old, when this cancer was previously reported predomi-
nantly in elderly women.4 Researchers struggled to find a link between 
the cancers until they discovered that seven of the eight women’s 
mothers took the drug DES while pregnant.5 
 Now that scientists were alerted to the potentially carcinogenic ef-
fects of DES on children in utero, they began to study the affects of 
DES in mice studies and compare those to humans exposed to DES in 
utero.6 Evidence from animal studies, and from studies monitoring the 
health of DES offspring, shows that DES children are at greater risk for 
a startling array of health ills: gross abnormalities in the shape and size 
of cervix and uteri; stunted penises and testes in sons; ectopic pregnan-
cies, miscarriages, and premature births in daughters; higher risk of 
prostate and breast cancers; and infertility in both sons and daughters.7 
 Endocrine-disrupting chemicals (EDCs) are chemicals, like DES, 
that interfere with human hormone processes.8 Endocrine disruptors 
have been linked to a litany of health harms, ranging from reproduc-
tive abnormalities to metabolic disorders like insulin resistance, type 2 
diabetes, and obesity.9 Additionally, EDC exposure in the womb has a 
disproportionately large affect on fetuses’ immediate and long-term 
health compared to EDC exposure in grown adults.10 While there are 
on-going scientific studies on DES, there has been far too little scien-
tific study of the potentially 87,000 chemicals that are also endocrine 
disruptors.11 This leaves society without enough information to deter-
mine whether or not to restrict the use of EDCs.12 
                                                                                                                      
4 Id. at 54–55; Ctrs. for Disease Control & Prevention, DES: Yesterday, Today, 
Tomorrow 1 (n.d.), available at http://www.cdc.gov/DES/consumers/download/know2_ 
des.pdf. 
5 See Colborn et al., supra note 2, at 55. Diesthylstilbestrol (DES), the first man-made 
estrogen, was developed in 1938. Id. 47–48. DES was immediately seen as a wonder drug for 
pregnant women, especially those at risk of miscarriage. Id. DES was widely prescribed be-
tween 1938 and 1971, initially to suppress miscarriage and later for other uses. Id. 
6 See id. at 58–59. 
7 Id. at 59; Ctrs. for Disease Control & Prevention, supra note 4, at 3. 
8 Colborn et al., supra note 2, at xv. 
9 Al Gore, Foreward to id. at vii; Noah Sachs, Blocked Pathways: Potential Legal Responses to 
Endocrine Disrupting Chemicals, 24 Colum. J. Envtl. L. 289, 290 (1999); Living on Earth: 
Bisphenol A on the Burner (Public Radio International broadcast Aug. 3, 2007) [hereinafter 
Living on Earth], available at http://www.loe.org/shows/segments.html?programID=07-P13- 
00031&segmentID=4 (interviewing two major endocrine disruption researchers, Dr. Ana 
Soto of Tufts University and Retha Newbold of the National Institute of Environmental 
Health Sciences, explaining their research into DES and BPA). 
10 See Colborn et al., supra note 2, at 73–74. 
11 See Sachs, supra note 9, at 302–03, 306. 
12 See id. 
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 In 1996, Congress recognized this concern and amended the Food, 
Drug, and Cosmetic Act to require the Environmental Protection 
Agency (EPA) to test all pesticides to determine their effects on the en-
docrine, or hormone, system.13 Although Congress gave EPA a strict 
three-year deadline to conduct these pesticide studies, EPA only began 
to mandate testing in 2009—ten years after its original deadline 
passed.14 Additionally, and most disturbingly, EPA’s testing policy allows 
pesticide companies to submit outdated testing data,15 data that in many 
cases is specifically designed to show these chemicals are safe.16 If EPA 
accepts outdated testing data instead of requiring new testing, pesticide 
companies will be allowed to side-step Congress’s explicit mandate that 
pesticides are to be tested for endocrine effects.17 If EPA does not force 
chemical companies to comply with new testing procedures it will fail to 
achieve the “ultimate purpose of the [testing program, which is] to pro-
vide information to the Agency that will allow the Agency to evaluate the 
risks associated with the use of a chemical and take appropriate steps to 
mitigate any risks.”18 If EPA fails to understand and properly mitigate 
risks from EDCs, society will continue to be exposed to potentially 
harmful chemicals on a daily basis.19 
 The purpose of this Note is to show that if EPA accepts outdated 
testing data, it will exceed its statutory authority, or alternatively, accept-
ing outdated test data is an arbitrary and capricious action.20 Congress 
in no uncertain terms dictated that EPA shall establish an endocrine 
testing program and shall test all pesticide chemicals under the testing 
program.21 However, EPA promulgated a testing order that potentially 
allows pesticide producers to submit outdated, inaccurate data.22 This 
Note argues, therefore, if EPA accepts outdated testing data, a review-
                                                                                                                      
13 Food Quality Protection Act of 1996, Pub. L. No. 104-170, 110 Stat. 1489 (codified as 
amended at 21 U.S.C. § 346a(p) (2006)); Colborn et al., supra note 2, at xvi. 
14 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 346a(p)(7) (2006); see Endo-
crine Disruptor Screening Program; Tier 1 Screening Order Issuing Announcement, 74 
Fed. Reg. 54,422, 54,425 (Oct. 21, 2009) [hereinafter Testing Order]. 
15 See Testing Order, supra note 14, at 54,427. 
16 Alexander C. Hart, Worries on Old Toxicity Data, L.A. Times, Oct. 17, 2009, at A18 
(“The order . . . would allow the pesticide makers to selectively submit outdated studies 
that show the pesticides are safe.”). 
17 See 21 U.S.C. § 346a(p). 
18 Endocrine Disruptor Screening Program; Policies and Procedures for Initial Screen-
ing, 74 Fed. Reg. 17,560, 17,561 (Apr. 15, 2009) [hereinafter Testing Policies]. 
19 See Colborn et al., supra note 2, at 110, 219. 
20 See Administrative Procedure Act, 5 U.S.C. § 706(2)(A), (C) (2006). 
21 21 U.S.C. § 346a(p). 
22 See Testing Order, supra note 14, at 54,427. 
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ing court must set aside the provision of the testing order allowing in-
dustry to submit old testing data in place of conducting new testing.23 
Furthermore, this Note argues that testing is an important first step, 
and should be extended to non-pesticide EDCs, but these chemicals 
must be properly regulated once EPA receives testing information. 
 Part I of this Note further explains what endocrine-disrupting 
chemicals are and enumerates their potential health harms.24 Part II 
explains the current statutory and regulatory framework for testing 
chemical effects on the endocrine system.25 Part III argues that the 
Administrative Procedure Act provides a tool for challenging EPA’s fi-
nal agency action as either in excess of statutory authority, or alterna-
tively, as arbitrary and capricious.26 Part IV identifies potential avenues 
for regulating EDCs that are found to negatively affect human health.27 
I. Endocrine-Disrupting Chemicals 
 EDCs include a wide-ranging group of man-made as well as natu-
rally occurring compounds that “trick the body and disrupt its own 
chemical messengers.”28 People absorb and store EDCs in small doses 
from many common sources every day.29 Small amounts of these 
chemicals are in everything from drinking water to plastics used for 
water bottles and food storage. Atrazine, an herbicide used widely on 
crops, golf courses, and lawns, is now among the most common pollut-
ants in drinking water.30 Bisphenol-A (BPA) is one of the most com-
monly used chemicals in plastics in the United States.31 
 EDCs were previously considered benign because people are ex-
posed to doses well below those that are fatal or known to cause can-
cer.32 However, scientific studies are beginning to show these chemicals 
are, counter-intuitively, often more dangerous in lower doses than in 
                                                                                                                      
23 See 5 U.S.C. § 706(2)(A), (C). 
24 See infra Part I. 
25 See infra Part II. 
26 See infra Part III. 
27 See infra Part IV. 
28 Colborn et al., supra note 2, at 68. 
29 See generally Rachel Carson, Elixirs of Death, in Silent Spring 15–37 (Houghton 
Mifflin 1994) (1962) (explaining the omnipresence of chemicals in the environment, and 
the storage and latency of DDT and other chemicals in the human body). 
30 Charles Duhigg, Debating How Much Weed Killer Is Safe in Your Water Glass, N.Y. Times, 
Aug. 23, 2009, at A1. 
31 Sachs, supra note 9, at 305. 
32 See Colborn et al., supra note 2, at 205. 
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massive doses.33 Scientists do not fully understand why small doses of 
EDCs can have greater ill effects than larger doses, especially because 
scientists generally expect that chemicals follow the adage “the dose 
makes the poison.”34 Nonetheless, it is clear that the body can be tricked 
into action by a hormone or hormone-mimicker at low doses, but as 
hormone levels rise the system eventually shuts off, thus stopping any ill 
effect.35 Additionally, it is clear that when it comes to endocrine disrup-
tors, the timing of exposure can have far more impact than the size of 
the dose.36 This is why exposure to EDCs in the womb can have such a 
large impact on the health of a developing fetus, especially when EDC 
exposure occurs at certain points in fetal development.37 A fetus ex-
posed to an EDC after sexual differentiation or other major develop-
mental milestone may suffer no ill effects, while a fetus exposed at cru-
cial points in development may be permanently harmed.38 
 Endocrine disruptors are linked to a wide range of maladies. 
Among other ill effects, EDCs can potentially cause infertility, obesity, 
immune disorders such as type 2 diabetes, and cancers.39 Although 
these disorders are wide-ranging, they all have a common link: these 
diseases affect components of the endocrine system.40 
A. The Endocrine System and Hormones 
 The endocrine system, along with the immune and nervous sys-
tems, is one of the major regulating and integrating systems in the hu-
man body.41 The endocrine system is composed of hormone-secreting 
glands including the pituitary, thyroid, and pancreas, among others.42 
Hormones regulate many of the body’s most important functions, in-
cluding metabolism, blood pressure, developmental mechanisms, and 
the nervous system.43 Hormones travel through the blood stream to 
                                                                                                                      
33 Id. 
34 Id. 
35 Id. at 206. 
36 Id. 
37 See id. at 43, 62. 
38 See Colborn et al., supra note 2, at 43, 62. 
39 See Sachs, supra note 9, at 290; Living on Earth, supra note 9. 
40 See Sachs, supra note 9, at 290; Living on Earth, supra note 9. 
41 Risk Assessment Forum, EPA, Special Report on Environmental Endocrine 
Disruption: An Effects Assessment and Analysis 2 (1997) [hereinafter EPA Study], 
available at http://www.p2pays.org/ref/07/06070.pdf. 
42 Id. 
43 Id. 
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hormone receptors.44 Once bonded to those receptors, hormones ex-
ert their influence and can cause systemic changes.45 Endocrine disrup-
tors can interfere with our endocrine system in many different ways.46 
EDCs can mimic our natural hormones and bond with receptors in or-
gans and tissues, interfere with receptor bonding, or enhance or inhibit 
naturally occurring hormones.47 EDCs’ interruption of normal hor-
mone functions can cause a cascade of effects.48 
 Additionally, and crucially, glands excrete hormones that act in 
infinitesimally small doses, registering as low as parts-per-trillion con-
centration in the bloodstream.49 Therefore, it potentially only takes a 
tiny amount of a hormone or hormone-mimicker to affect huge 
changes in our bodies, particularly at crucial points in development.50 
EDCs therefore have a significantly more pronounced effect on fetuses 
than on adults, and correspondingly “[t]here are . . . concerns that ex-
posure to low doses of certain chemicals at critical stages in organ de-
velopment can result in abnormalities that lead to irreversible changes 
in the functioning of organ systems later in life.”51 Hormones in the 
womb are responsible for permanently programming cells, organs, the 
brain, and behavior, profoundly influencing physical and mental char-
acteristics of the developing fetus.52 
 The consequences of malfunctioning hormones in the womb can 
appear immediately after birth, as physical deformities, but also in 
long-term diseases that arise well into adulthood.53 For example, chil-
dren whose mothers took the synthetic estrogen drug DES during 
pregnancy were not only born with physical abnormalities that were 
evident at birth,54 they also were at greater risk for different kinds of 
                                                                                                                      
44 Id. 
45 See id. 
46 See Colborn et al., supra note 2, at xvi. 
47 See Sachs, supra note 9, at 293 (describing the ways in which EDCs can interfere with 
normal hormone function). 
48 See id. 
49 Colborn et al., supra note 2, at 40. 
50 See id. at 40–42. 
51 Nat’l Research Council, Nat’l Academies, Hormonally Active Agents in the 
Environment 119 (1999) [hereinafter NRC Report], available at http://www.nap.edu/open 
book.php?record_id=6029&page=R1. 
52 Colborn et al., supra note 2, at 39–40. 
53 Id. at 57–58. 
54 Id. at 59. 
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cancer, auto-immune diseases, and depression later in life.55 On-going 
research is discovering other long-range harms.56 
B. Some Common Endocrine-Disrupting Chemicals 
 Many common chemicals are known or suspected to interact with 
the endocrine system, and thus are in the family of endocrine disrup-
tors.57 Some of the most common classes of EDCs are described below. 
1. Pharmaceuticals 
 Drugs like DES are designed specifically to mimic hormones.58 
There is popular concern that excess estrogen from birth-control pills, 
which are a synthetic version of estrogen and progestin, makes its way 
out of women’s bodies, into wastewater treatment plants, and out into 
major water bodies.59 However, estrogen from drugs used in humans 
accounts for approximately one percent of estrogen in the environ-
ment.60 Meanwhile, approximately ninety percent of estrogen in the 
environment comes from livestock operations.61 This is the result of 
injecting livestock with growth hormones and leaving hormone-rich 
manure untreated, which runs into surface and ground waters.62 Re-
gardless of the direct source, estrogenic pharmaceuticals are a signifi-
cant source of endocrine disruptors in the environment.63 
2. Estrogenic Additives 
 Compounds with estrogenic effects are widely used in detergents, 
paints, herbicides, pesticides, and cosmetics.64 These chemicals are 
washed out of our homes and off our lawns in huge quantities.65 Estro-
                                                                                                                      
55 Id. at 62, 63, 65. See generally Ctrs. for Disease Control & Prevention, Recent 
DES Research (n.d.), available at http://www.cdc.gov/DES/consumers/download/learn-
ing2_research.pdf. 
56 See id. 
57 See id. 
58 Colborn et al., supra note 2, at 48. 
59 See id. at 133; Nicholas D. Kristoff, It’s Time to Learn from Frogs, N.Y. Times, June 28, 
2009, at WK9. 
60 Endocrine Disrupting Compounds and Intersex Fish, UCSF Program Reprod. Health & 
Env’t, http://prhe.ucsf.edu/prhe/learn/kristof_edcs.html (last visited Apr. 15, 2011). 
61 Id. 
62 Id.; Ariele Lessing, Killing Us Softly: How Sub-Theraputic Dosing of Livestock Causes Drug-
Resistant Bacteria in Humans, 37 B.C. Envtl Aff. L. Rev. 463, 467–68 (2010). 
63 See id. 
64 Colborn et al., supra note 2, at 129; Sachs, supra note 9, at 304. 
65 See Sachs, supra note 9, at 304. 
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genic additives that wash away either pass through water treatment sys-
tems or run directly into surface and ground waters, often polluting 
water bodies with high concentrations of estrogenic additives.66 These 
water bodies then serve as drinking water sources.67 These estrogenic 
additives have shown serious endocrine effects in fish. When govern-
ment fisheries staff in England discovered that fish near the outfalls of 
wastewater treatment plants exhibit both male and female characteris-
tics, referred to as “intersex,” they investigated the source of the fishes’ 
sexual confusion.68 The major culprit turned out to be the detergents 
we use to clean our clothes and houses, which breaks down into the 
alkylphenol family of chemicals that act as estrogen mimickers.69 
3. Pesticides 
 Endocrine-disrupting pesticides include infamous compounds 
such as DDT and kepone.70 DDT was banned as a general use pesticide 
in the United States in 1972,71 but is still manufactured for sale over-
seas.72 However, DDT and other pesticides persist in the U.S. environ-
ment because they build up and remain stored in the fatty deposits of 
wildlife and humans.73 This means that organisms further up the 
predatory food chain have larger concentrations of DDT in their sys-
tems.74 Though DDT is banned as a pesticide, many pesticides still used 
on crops have similar impacts: heightening estrogen effects in the body 
while suppressing testosterone function.75 
4. Industrial Chemicals 
 This class of suspected endocrine disruptors includes polychlori-
nated biphenyls (PCBs), which were used as heat transfer and hydraulic 
fluids, adhesives, and flame retardants among other purposes.76 Con-
gress banned production of most PCBs in 1976, but similar to DDT, PCBs 
                                                                                                                      
66 See Colborn et al., supra note 2, at 129; Sachs, supra note 9, at 304. 
67 See Colborn et al., supra note 2, at 129; Sachs, supra note 9, at 304. 
68 Colborn et al., supra note 2, at 132. 
69 See id. at 134. 
70 See Sachs, supra note 9, at 303. 
71 Press Release, EPA, DDT Ban Takes Effect (Dec. 31, 1972), available at http://www. 
epa.gov/history/topics/ddt/01.htm. 
72 See id. 
73 Carson, supra note 29, at 24, 48, 108. 
74 Id. at 48. 
75 See Sachs, supra note 9, at 303. 
76 Id. at 304. 
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persist in the environment and bio-accumulate in the food chain.77 PCBs 
are particularly prevalent in fish that live in contaminated waters.78 
                                                                                                                     
5. Bisphenol-A (BPA) 
 BPA has gained national recognition in the past three years.79 BPA, 
a “strong and resilient plastic,” is one of the highest production volume 
EDCs because it is used in a wide variety of products.80 BPA is used in 
plastic water bottles—including the popular Nalgene brand, which has 
recently switched to non-BPA plastics—contact lenses, baby bottles, and 
as a liner for many canned food products including infant formula.81 
BPA has been shown to interfere with hormone activity at very low lev-
els, and there is concern that BPA causes an increase in prostate cancer, 
breast cancer, early onset of puberty in girls, and neurobehavioral prob-
lems.82 
C. Endocrine Disruption in Humans 
 There is a paucity of scientific studies directly linking EDCs to hu-
man health effects, which is precisely why Congress directed EPA to 
implement a testing program.83 To date, EPA has not conducted any 
endocrine chemical testing, and independent scientists have only stud-
ied the human health effects of select endocrine disruptors, among 
them BPA.84 This is primarily because BPA is used in so many products 
that exposure to BPA is nearly universal.85 A recent study by the Cen-
ters for Disease Control and Prevention found that ninety-five percent 
of people tested have traces of BPA in their urine.86 Additionally, a re-
cent study commissioned by the Environmental Working Group found 
that nine out of every ten samples of blood taken from umbilical cords 
 
77 Id. at 304; Colborn et al., supra note 2, at 27. 
78 Sachs, supra note 9, at 304. 
79 Editorial, Heightened Concern over BPA, N.Y. Times, Jan. 21, 2010, at A38. 
80 See Living on Earth, supra note 9. 
81 Sachs, supra note 9, at 305; Living on Earth, supra note 9; Elaine Shannon, BPA: Why 
Are We Still Easting This Stuff?, Envtl. Working Group (Jan. 18, 2010), http://www.ewg. 
org/kid-safe-chemicals-act-blog/2010/01/bpa-why-are-we-still-eating-this-stuff/. 
82 See Living on Earth, supra note 9. 
83 Sachs, supra note 9, at 306; see Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 
§ 346a(p)(2006). 
84 See Testing Order, supra note 14, at 54,427; Living on Earth, supra note 9. 
85 See supra Part I.B.5. 
86 Living on Earth, supra note 9. 
518 Environmental Affairs [Vol. 38:509 
of newborn babies shows BPA contamination.87 The effect of endocrine 
disruption on fetal development is much greater than in adults, and 
can lead to both immediate and life-long health consequences for an 
exposed fetus.88 Although it is challenging to establish a causal link be-
tween exposure to endocrine disruption and specific outcomes in hu-
mans, scientific studies have shown a strong association between BPA 
and many health effects: cognitive and behavioral impairments, repro-
ductive system abnormalities, obesity, and some cancers.89 Additionally, 
scientists have found a parallel between BPA and DES exposure, be-
cause both cause cystic ovaries and uterine fibroids.90 
 DES is fairly unique case study because it provides one of the few 
clear, direct causal links between EDCs and human health effects.91 Of 
course, the unintended experiment with human health came with seri-
ous health consequences for DES-exposed offspring.92 Animal studies 
are a useful addition to epidemiological studies on EDC effects in hu-
mans. Animal studies can aid in defining causal links, and potentially 
have much to teach us about endocrine disruption in humans. 
D. Endocrine Disruption in Animals 
 Although there is concern in inferring human effects from endo-
crine disruption observed in animals, there is good reason to consider 
animal studies when trying to understand EDC’s effect on humans.93 
The most important reason comes from DES and BPA studies in 
mice.94 Once concerns about DES and BPA arose, scientists began con-
trolled mouse studies to isolate cause and effect of administering these 
endocrine disruptors to mice in utero.95 As researcher Retha Newbold 
stated, “[human health effects] are things that we actually predicted 
with [DES] animal studies.”96 Another researcher who conducted DES 
mouse studies, John McLachlan, 
                                                                                                                      
87 See Envtl. Working Group, Pollution in People: Cord Blood Contaminants 
in Minority Newborns 8 (2009), available at http://www.ewg.org/files/2009-Minority-
Cord-Blood-Report.pdf. 
88 See supra Part I.A. 
89 Sachs, supra note 9, at 306; Living on Earth, supra note 9. 
90 Living on Earth, supra note 9. 
91 See supra Introduction. 
92 See supra notes 5–7 and accompanying text. 
93 See Sachs, supra note 9, at 293–94. 
94 See Colborn et al., supra note 2, at 58–59; Living on Earth, supra note 9. 
95 See Colborn et al., supra note 2, at 58–59; Living on Earth, supra note 9. 
96 Living on Earth, supra note 9. 
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kept in close touch with Dr. Arthur “Hap” Haney, a physician 
. . . who was treating humans exposed to DES. Time and time 
again, McLachlan would find something in a mouse and dis-
cover, when he called Haney, that the physician had seen the 
same problem in humans as well. Once in a while, the mouse 
findings would signal problems long before they emerged in 
humans.97 
Accordingly, endocrine effects in animals are often predictors of endo-
crine effects in humans.98 
 There are also many startling examples of endocrine disruption in 
wild animals that warn of potential endocrine effects in humans.99 For 
example, the effect of DDT on bird species gained widespread recogni-
tion with Rachel Carson’s seminal 1962 book, Silent Spring.100 Carson 
described scientific studies that showed striking examples of EDC bio-
accumulation in robin populations.101 The high levels of DDT in bird 
testes and ovaries led to females who either could not lay eggs at all or 
laid eggs that were so defective that they did not hatch.102 
 The BPA and DES mouse studies showed that endocrine disrup-
tion in animals can often predict the course of endocrine disruption in 
humans.103 Additionally, the DDT robin observations should serve as a 
warning about potential endocrine effects in humans.104 Some of these 
particular studies are only of limited use, because they served their pur-
pose—DES is no longer sold, and DDT is now banned as a general use 
pesticide.105 Nonetheless, BPA remains in heavy use in the United 
States, regardless of the scary science that has emerged regarding BPA’s 
endocrine effects.106 Therefore, it is important to expand research and 
learn more about the affects of other EDCs that humans more com-
monly encounter on a daily basis.107 
                                                                                                                      
97 Colborn et al., supra note 2, at 59. 
98 See id. 
99 See Carson, supra note 29, at 103–27 (chronicling the effects of EDCs on robins and 
eagles). 
100 See generally id. (discussing the widespread use of DDT and its effect on bird species). 
101 See id. at 107–09. 
102 See id. at 108–09. 
103 See Colborn et al., supra note 2, at 59. 
104 See id. 
105 Supra Part I.B.3. 
106 See supra notes 80 and 96 and accompanying text. 
107 See Sachs, supra note 9, at 302–03. 
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E. Implications for Regulations 
 Existing science has begun to show that two key issues impact how 
EDCs affect animals and humans. First, when exposure occurs can make 
a big difference, especially if EDC exposure occurs during key stages of 
fetal development.108 Therefore, it is crucial for future research 
to focus not only on direct mortality, but also on the far more 
common, but less easily measured, sublethal effects of endo-
crine disruption which may have detrimental consequences to 
populations in the long-term (and especially as these disrup-
tions occur to embryos, adversely affecting the organization of 
the reproductive, immune, or nervous systems).109 
Second, how much of an endocrine disruptor is needed to affect change 
can vary, and the effects of the same EDC can change when exposure 
occurs at different doses.110 In fact, “testing with very high doses will 
miss some effects that would show up if the animals were given lower 
doses.”111 Therefore, it is important to test the same EDC at different 
doses, in order to understand what changes it causes at different 
doses.112 It is crucial to learn more about the relationship between dose-
response, and timing of exposure and response, in order to properly 
police human exposure to EDCs through legislation and regulation.113 
II. The Statutory and Regulatory Framework for Testing 
Endocrine-Disrupting Chemicals 
 Existing science shows that EDCs are a threat to human health and 
the environment.114 However, more specific scientific studies are 
needed in order to have a comprehensive picture of which chemicals 
are endocrine disruptors, and at what doses and in what manner these 
                                                                                                                      
108 See Colborn et al., supra note 2, at 62 (“Women whose mothers took DES after the 
twentieth week of pregnancy do not suffer from the reproductive tract deformities, while 
those exposed before the tenth week of pregnancy have a greater chance of developing 
vaginal or cervical cancer.”). 
109 EPA Study, supra note 41, at 67. 
110 See Pete Meyers & Wendy Hessler, Does “the Dose Make the Poison?” 1 (2007), 
available at http://www.ourstolenfuture.org/newscience/lowdose/2007/2007-0525nmdrc.html 
(showing that mice exposed to DES at one part per billion grow to be grossly obese, while mice 
exposed to DES at 100 parts per billion are scrawny as adults.). 
111 Colborn et al., supra note 2, at 170. 
112 See Meyers & Hessler, supra note 110, at 2–3. 
113 See id. at 4. 
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chemicals act as endocrine disruptors in fetal, child, and adult hu-
mans.115 Partially in recognition of this issue, Congress passed the Food 
Quality Protection Act of 1996, which requires EPA to test pesticide 
chemicals for endocrine-disrupting properties, and regulate those pesti-
cides accordingly.116 
                                                                                                                     
A. The Estrogenic Substances Screening Program 
 The Food Quality Protection Act was designed to reform pesticide 
regulation and evaluate tolerances for pesticide residue in foods.117 
Motivated by the recent widespread attention to endocrine disruption 
following the publication of Our Stolen Future,118 Congress included a 
provision in the Food Quality Protection Act to establish an endocrine 
screening program under the Federal Food, Drug, and Cosmetic Act.119 
1. Structure of the Estrogenic Substances Screening Program 
 The Estrogenic Substances Screening Program under the Federal 
Food, Drug, and Cosmetic Act directs EPA to establish a testing program 
to determine if certain substances have endocrine effects.120 Specifically, 
it requires that the Administrator of the EPA “provide for the testing of 
all pesticide chemicals” for endocrine effects,121 and gives the Adminis-
trator discretion to test any other substance that “may have an effect that 
is cumulative to an effect of a pesticide” if a “substantial population” is 
exposed to the substance.122 Therefore, although the Administrator is 
not required to test chemicals beyond pesticides, she is allowed discre-
tion to test other substances with similar effects that reach a wide popu-
lation, for example, BPA.123 Additionally, although limited, Congress did 
give EPA enforcement mechanisms to obtain test results from anyone 
ordered to test a pesticide who fails to do so.124 
 
115 See id. at 73–74; Sachs, supra note 9, at 300. 
116 Food Quality Protection Act of 1996, Pub. L. No. 104-170, 110 Stat. 1489 (codified 
as amended in 21 U.S.C. § 346a(p) (2006)). 
117 142 Cong. Rec. 18,588 (1996). 
118 See, e.g., Colborn et al., supra note 2, at xv–xvi. 
119 See 21 U.S.C. § 346a(p). 
120 Id. § 346a(p)(1). 
121 Id. § 346a(p)(3)(A). 
122 Id. § 346a(p)(3)(B). 
123 See id.; supra Part II.B.5. 
124 21 U.S.C. § 346a(p)(5)(C)–(D). 
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2. Enforcement Mechanisms Under the Screening Program 
 The screening program does specifically provide sanctions against 
parties that refuse to comply with testing procedures for suspected 
EDCs.125 The statute allows EPA to suspend the sale or distribution of a 
pesticide with a thirty day notice if the manufacturer of the substance 
refuses to comply with a testing order.126 Additionally, parties other 
than pesticide registrants who fail to comply with testing orders—most 
likely non-pesticide producing parties who are required to provide data 
or conduct testing under the screening program—can be penalized 
under the Toxic Substances Control Act, which carries civil penalties up 
to $25,000.127 
B. Endocrine Disruptor Screening and Testing Advisory Committee 
 While Congress granted the EPA Administrator wide latitude in 
determining which substances to test and in designing the screening 
program, it kept EPA to a very tight timetable.128 Congress only gave 
EPA two years to develop the program, another year to conduct testing, 
and expected EPA to submit a report on the testing by 2000—four years 
after the Food Quality Protection Act was passed.129 This timeline 
proved to be too ambitious. In fact, EPA only issued the first round of 
testing orders in October 2009,130 which will not be completed until 
October 2011 at the earliest.131 Thus, it will be years until EPA can de-
liver a report to Congress. 
 In 1996, EPA began the task of selecting which pesticide chemicals 
to test first, and designing and implementing a testing program, by 
convening an Endocrine Disruptor Screening and Testing Advisory 
Committee (EDSTAC).132 EDSTAC was composed of stakeholders from 
various sectors: environmental groups, federal agencies, state agencies, 
public health organizations, industry, and scientists.133 EDSTAC worked 
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for two years to set priorities among potential EDCs, and to design an 
appropriate screening and testing program.134 
 EDSTAC issued a final report in August 1998, with numerous rec-
ommendations.135 EDSTAC recommended that the testing program 
should focus on endocrine effects on three primary hormone systems: 
the estrogen, androgen, and thyroid systems.136 EDSTAC recognized 
that approximately 87,000 chemicals need to be tested for their endo-
crine-disrupting capabilities, but with limited resources, EPA must set 
priorities among the sea of chemicals to be treated.137 Additionally, 
EDSTAC suggested that EPA incorporate a two-tier system to test pesti-
cides.138 Tier one is designed to separate out chemicals that do not in-
teract with the endocrine system from those that do, so only established 
endocrine disruptors are subject to the next step of tier two testing.139 
 EPA essentially adopted EDSTAC’s finding and published a notice 
in the Federal Register announcing the newly established Endocrine 
Disruptor Screening Program (the “Testing Program”), designed to 
reflect the recommendations of EDSTAC.140 
C. The Testing Program 
 The Testing Program includes all the recommendations of ED-
STAC, including a tier one and tier two testing structure.141 Addition-
ally, EPA identified the criteria by which it would select and prioritize 
pesticides to test under the Testing Program.142 
 The years from 1999 to 2008 were plagued by delays in moving the 
Testing Program forward.143 Finally, the Natural Resources Defense 
Council (NRDC) filed suit against EPA to compel further action on the 
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Testing Program.144 A final consent decree required EPA to abide by its 
settlement agreement with NRDC and begin screening chemicals un-
der the Testing Program.145 Although the settlement agreement spe-
cifically provided that EPA would test thirty-nine pesticides for their 
endocrine-disrupting properties by 2002,146 there is no indication that 
EPA conducted such testing. In fact, EPA did not act until 2007, when it 
published a notice identifying the draft list of pesticides it would priori-
tize for testing.147 
D. Methods Required Under the Testing Program 
 It was another two years before EPA next took significant action 
under the Testing Program. In 2009, EPA published a proposed notice 
of the policies and procedures for tier one testing148 and the final list of 
initial pesticides prioritized for testing, which included sixty-seven pes-
ticides.149 The goal of tier one testing “is to identify substances that 
have the potential to interact with the estrogen, androgen, or thyroid 
hormone systems.”150 To achieve this goal, EPA designed the specific 
tests these pesticides must go through, factoring in all current scientific 
knowledge.151 Thus, the final testing battery for pesticides reflects up-
to-date science that takes into account, for example, the fact that when 
exposure occurs can significantly change an EDC’s health effect.152 EPA 
has not yet promulgated rules for tier two testing, but EPA has stated 
that the purpose of tier two testing is to “establish a dose-response rela-
tionship for any adverse effects that might result from the interactions 
identified through [Tier 1].”153 Therefore, tier two testing aims to es-
tablish the relationship between the amount of EDC—i.e., dose—and 
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effect on the organism—i.e., response—for those pesticides that ini-
tially demonstrate endocrine-disrupting properties.154 
 EPA included a concession in its policies and procedures that “re-
cipients of . . . test orders [have] the option of submitting or citing ex-
isting data, along with a rationale that explains how the cited or submit-
ted study satisfies the Tier 1 Order.”155 EPA was trying to be fair with 
this concession: EPA would allow individuals who receive test orders to 
submit previously conducted tests, so long as the prior data is designed 
to show whether or not the pesticide has an effect on the endocrine 
system.156 Therefore, EPA clearly states that any previously conducted 
data must satisfy the specific, up-to-date testing methods under the tier 
one protocol.157 
E. Final Hurdle to Testing: Approval under the Paperwork Reduction Act 
 EPA had one last hurdle to clear before issuing the first testing or-
ders: it had to obtain approval to issue testing orders from the Office of 
Management and Budget (OMB).158 This is due to the Paperwork Re-
duction Act, which mandates that any federal agencies wishing to col-
lect information from the public must meet certain criteria.159 Specifi-
cally, an agency must submit its proposal to collect information to OMB 
and get approval before collecting any information from the public.160 
When EPA issues a test order, it requests information from the public, 
which, in this case, consists of pesticide producers.161 Therefore EPA 
was required to draft an information collection request and submit it to 
OMB for approval.162 
 Unfortunately, the information request that OMB approved in-
cluded a major modification to the proposal drafted by EPA.163 EPA’s 
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Testing Program required new, up-to-date tests properly constructed to 
show endocrine effects, but allowed an exception for “functionally 
equivalent” data from old tests.164 The approved information request 
form from OMB, however, states that, 
under the principles of the [Paperwork Reduction Act], EPA 
should promote and encourage test order recipients to sub-
mit Other Scientifically Relevant Information (OSRI) in lieu 
of performing all or some of the Tier I [tests], and EPA 
should accept OSRI as sufficient to satisfy the test orders to 
the greatest extent possible.165 
The OMB approval also demanded that EPA report to OMB every in-
stance where it found that other scientifically relevant data was insuffi-
cient to satisfy the testing order.166 Ironically, OMB created these bur-
dens for EPA under a statute with the purpose of minimizing 
paperwork and reducing the cost of collecting information to the fed-
eral government.167 
 Beyond the burden imposed on EPA, this language is concerning 
because previous data generally comes from industry-developed re-
search that is designed to show that their chemicals do not cause unrea-
sonable endocrine effects.168 Older testing models are based on out-
dated science that may allow some endocrine effects to go 
unnoticed.169 If EPA is encouraged to accept outdated testing data that 
indicates chemicals are not endocrine disruptors—even when modern 
test may show endocrine effects—then the entire purpose of the Test-
ing Program will be undermined.170 Thus, although the OMB is not 
preventing EPA from achieving its purpose, OMB is making EPA’s job 
more difficult and encouraging it to rely on outdated, ineffective test-
ing methods and data.171 
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III. The Administrative Procedure Act Should Be Used to 
Compel New Testing 
 As noted by Congress at the passing of the Food Quality Protection 
Act, “[t]he ultimate success of this reform will rest with the profession-
alism and the common sense of the Environmental Protection Agency. 
Congress will be watching closely as we try to implement these reforms. 
We will, to ensure that science, not emotion, is the basis of pesticide 
regulation.”172 However, if EPA accepts old test data that does not con-
form to tier one testing standards, then EPA has not lived up to its 
“common sense” mandate.173 Congress has thus far failed to “closely 
watch” EPA and OMB to ensure pesticides are tested with current tech-
nology to assess their endocrine-disrupting potential.174 Therefore, it is 
up to citizens to monitor EPA’s progress in obtaining and reviewing test 
data to ensure the Agency is carrying out its congressional mandate.175 
A. Administrative Procedure Act 
 If citizens are discouraged with EPA’s progress in testing pesticides 
under the Endocrine Disruptor Screening Program, the Administrative 
Procedure Act (APA) offers a potential solution.176 Specifically, the APA 
provides that a “person suffering legal wrong because of agency action, 
or adversely affected or aggrieved by agency action within the meaning 
of a relevant statute, is entitled to judicial review thereof.”177 Further-
more, the APA states that a reviewing court must either compel or set 
aside agency action found to be: (1) “arbitrary, capricious, an abuse of 
discretion, or otherwise not in accordance with law”; or (2) “in excess 
of statutory jurisdiction, authority, or limitations, or short of statutory 
right.”178 If EPA does accept outdated, unreliable testing data then 
nearly any member of the public is a person aggrieved within the mean-
ing of the Food Quality Protection Act of 1996, as we are all regularly 
exposed to endocrine-disrupting pesticides and other EDCs that the 
Act is designed to test and regulate.179 If an aggrieved citizen did bring 
a claim under the APA to challenge EPA’s testing rules and program, a 
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reviewing court would review the agency action using the Chevron stan-
dard. 
B. Chevron and Agency Statutory Interpretation 
 In Chevron U.S.A., Inc. v. Natural Resources Defense Council, the Su-
preme Court outlines the process for judicial review of an administra-
tive agency’s interpretation of its statutory authority.180 Specifically, the 
Chevron Court directed: 
 When a court reviews an agency’s construction of the stat-
ute which it administers, it is confronted with two questions. 
First, always, is the question whether Congress has directly 
spoken to the precise question at issue. If the intent of Con-
gress is clear, that is the end of the matter; for the court, as 
well as the agency, must give effect to the unambiguously ex-
pressed intent of Congress. 
 If, however, the court determines Congress has not directly 
addressed the precise question at issue. . . . [I]f the statute is 
silent or ambiguous with respect to the specific issue, the 
question for the court is whether the agency’s answer is based 
on a permissible construction of the statute.181 
 Under this analysis, a court must look to the statutory language to 
determine if it is unambiguous and thus communicates clear congres-
sional intent.182 If the statutory language is clear, and the agency has 
acted within the bounds of the statutory language, then the analysis is 
done.183 However, as the Court further notes, “[t]he judiciary . . . must 
reject administrative constructions which are contrary to clear congres-
sional intent.”184 
B. EPA Will Fail to Fulfill Its Congressional Mandate If It Accepts  
Outdated Testing Data 
 If EPA accepts outdated testing results, a court reviewing a chal-
lenge to EPA’s Testing Program would most likely find that the Agency 
acted in excess of statutory jurisdiction and therefore the provision al-
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lowing old test data would be set aside.185 The statutory language man-
dating the Testing Program is unambiguous.186 The Screening Program 
specifically directs that EPA “shall develop a screening program, using 
appropriate validated test system” and “shall provide for the testing of all 
pesticide chemicals” in order to implement the new testing system.187 
Although Congress affords EPA discretion in selecting which chemicals 
to test beyond pesticides, Congress was unambiguous in directing the 
Agency to develop a new testing program to establish endocrine effects 
of all pesticides.188 EPA’s decision to accept old testing data at best side-
steps, and potentially contradicts, Congress’s clear mandate to EPA.189 
 If EPA does actually accept old test data not designed to show if a 
chemical acts as an endocrine disruptor, then EPA is not, as the APA 
requires, acting within its statutory authority.190 This is because Con-
gress only granted EPA discretion in how to structure the testing pro-
gram, but did not delegate the ability to choose whether or not to test 
pesticides for their endocrine effects.191 EPA must test all pesticides for 
endocrine effects, and has failed to do so if it allows for submission of 
old data from tests incapable of detecting endocrine effects.192 Thus, a 
reviewing court will likely determine that EPA is not entitled to Chevron 
deference in this situation, and must instead abide by its clear statutory 
directive to execute the endocrine testing program.193 A court can thus 
stop at the initial inquiry, and as a result, an arbitrary and capricious 
analysis is not necessary.194 
C. Arbitrary and Capricious Standard 
 If, however, a reviewing court found that EPA did not act in opposi-
tion to its clear statutory mandate to test pesticides, there is an addi-
tional avenue for relief.195 Even when a court has determined that an 
agency has acted within the scope of its statutory authority, agency ac-
                                                                                                                      
185 See Chevron, 467 U.S. at 843. 
186 See Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 346a(p)(1), (3)(A) (2006). 
187 Id. (emphasis added). 
188 See id. 
189 See id. 
190 See Administrative Procedure Act, 5 U.S.C. § 706(2)(C)(2006). 
191 See 21 U.S.C. §§ 346a(p)(1), (3)(A). 
192 See id. 
193 See id. §§ 346a(p)(1), (3)(A); Chevron U.S.A. v. Natural Res. Def. Council, 467 U.S. 
837, 843 (1984); supra Part III.F.1. 
194 See Motor Vehicle Mfg. Ass’n of the U.S. v. State Farm Mut. Auto. Ins., 463 U.S. 29, 
42–43 (1983). 
195 Citizens to Protect Overton Park v. Volpe, 401 U.S. 402, 416 (1971). 
530 Environmental Affairs [Vol. 38:509 
tion can nonetheless be set aside if it is “arbitrary, capricious, an abuse 
of discretion, or otherwise not in accordance with law.”196 In Motor Vehi-
cle Manufacturers Ass’n of the United States v. State Farm Mutual Automobile 
Insurance, the Court identified a series of factors to analyze when con-
sidering whether or not an agency action is arbitrary and capricious: 
Normally, an agency rule would be arbitrary and capricious if 
the agency has [1] relied on factors which Congress has not in-
tended it to consider, [2] entirely failed to consider an impor-
tant aspect of the problem, [3] offered an explanation for its 
decision that runs counter to the evidence before the agency, 
or [4] is so implausible that it could not be ascribed to a dif-
ference in view or the product of agency expertise.197 
There is a compelling argument under these factors that EPA’s action 
in establishing the Testing Program was arbitrary and capricious.198 In 
particular, the record regarding the Testing Program shows that if it 
chooses to accept old data, EPA “entirely failed to consider an impor-
tant aspect of the problem,” and its decision would be “so implausible 
that it could not be ascribed to a difference in view.”199 
D. If EPA Accepts Outdated Test Data, Its Actions  
Are Arbitrary and Capricious 
 A court engaging in an arbitrary and capricious analysis would look 
to EPA’s record in formulating the Testing Program, and determine 
whether or not EPA articulated a satisfactory explanation for its action, 
including a rational connection between facts and final action.200 EPA’s 
record includes: the Endocrine Disruptor Screening and Testing Advi-
sory Committee (EDSTAC) recommendations to the Agency; EPA’s 
promulgation of rules adopting EDSTAC’s testing suggestions; and 
EPA’s policies and procedures for the testing program.201 EDSTAC’s 
report and even EPA’s policies and procedures clearly state that previ-
ously conducted test data is only acceptable if it conforms to tier one 
testing standards.202 There is no rational connection between the re-
cord, which clearly calls for new, higher-technology testing of pesticides, 
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and an agency action that would accept outdated test data.203 Addition-
ally, if EPA does not submit pesticides to higher-technology standards 
like those under the tier one testing protocol, they will have “failed to 
consider an important aspect of the problem.”204 Therefore, if EPA de-
cides to accept outdated test data that is not designed to show endocrine 
effects, that decision will most likely be found to be arbitrary and capri-
cious.205 A reviewing court would thus set aside the portion of the final 
rule allowing for outdated test data in lieu of conducting new testing 
under the tier one testing protocol.206 
 Although the APA provides potent tools for a citizen suit to en-
force Congress’ intended Testing Program, test data is only valuable 
once its findings are applied to the regulation of endocrine disruptors. 
IV. Regulating Established Endocrine Disruptors 
 It is currently unclear what will happen after EPA completes the 
Testing Program and reports back to Congress. The Testing Program 
includes a sweeping statement that “any substance that is found, as a 
result of testing and evaluation under this section to have an endocrine 
effect on humans, the [EPA] Administrator shall, as appropriate, take 
action under such statutory authority as is available . . . necessary to en-
sure the protection of public health.”207 This language is incredibly 
broad and discretionary, which makes it unclear how EPA will ulti-
mately regulate pesticides and other chemicals that are found to have 
endocrine effects through the Testing Program.208 
 Congress likely did not provide EPA a new regulatory structure for 
controlling EDCs because existing statutes already provide EPA the abil-
ity to regulate pesticides and toxic substances.209 However, it will likely 
be up to citizen enforcers to take the lead in ensuring that EPA acts on 
the data it collects, and takes steps to regulate proven EDCs to protect 
human health and the environment. Two major statutes provide ave-
nues for regulating EDCs: the Federal Insecticide, Fungicide, and Ro-
denticide Act, and the Toxic Substances Control Act.210 
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A. Federal Insecticide, Fungicide, and Rodenticide Act 
 Under the Federal Insecticide, Fungicide, and Rodenticide Act 
(FIFRA), EPA regulates pesticides’ entry into the market through label-
ing, sale, and distribution regulations.211 It is important to note that 
FIFRA only applies to pesticide chemicals.212 FIFRA first provides that 
all new pesticides must be registered with EPA.213 EPA must approve 
registrations for pesticides that perform their intended function “with-
out unreasonable adverse effects on the environment.”214 “Unreason-
able adverse effects on the environment” are further defined as “any 
unreasonable risk to man or the environment, taking into account the 
economic, social, and environmental costs and benefits of the use of 
any pesticide.”215 Therefore FIFRA has an inherent cost-balancing test 
within its regulatory structure.216 However, EPA can cancel a registra-
tion and take a pesticide off the market if it finds that the pesticide 
causes an unreasonable adverse effect, subject to this cost-benefit bal-
ancing test.217  
 However, this method of regulating pesticides under FIFRA poses 
significant problems. First, under FIFRA economic costs are frequently 
given far more emphasis in the balancing test than issues like endo-
crine disruption.218 Therefore it is challenging to get a pesticide regis-
tration cancelled.219 Additionally, even if EPA does cancel a registra-
tion, a blanket prohibition on selling a particular pesticide is a blunt, 
extreme solution. That is because FIFRA is a front-end statute; it is de-
signed to control the entry point of pesticides, but has little ability to 
fine tune the use of pesticides after registration.220 Although a crude 
solution, the ability to cancel a registration under FIFRA at least pro-
vides one avenue for regulating pesticides under existing environ-
mental law, and could provide an avenue for relief if the Testing Pro-
gram shows that a particular pesticide is highly toxic with widespread 
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endocrine disruption. Again, pesticides are the only class of endocrine 
disruptors EPA is currently required to test under the Testing Program, 
so having a regulatory structure to manage pesticides, even an imper-
fect one, is crucial.221 
B. Toxic Substances Control Act 
 The Toxic Substances Control Act (TSCA) is a broader and poten-
tially more helpful statute than FIFRA. TSCA allows EPA to test and 
regulate certain chemical substances.222 The threshold test for whether 
or not EPA can act under TSCA is whether or not a chemical “pre-
sent[s] an unreasonable risk of injury to health or the environment.”223 
If EPA reasonably concludes that a chemical does present an unreason-
able risk of injury to health or the environment, it can require further 
testing or restrict a chemical’s use.224 However, EPA is significantly lim-
ited in testing and regulating chemicals because TSCA further inter-
prets “unreasonable risk of injury to health or the environment” to in-
clude a cost-balancing requirement.225 This means that EPA must take 
into account the benefits of the chemical, availability of substitutes, and 
economic consequences of when it considers restricting a chemical.226 
Additionally, TSCA only allows EPA to impose “the least burdensome” 
restrictions necessary to protect against unreasonable risk.227 In prac-
tice, this means EPA has rarely limited toxic chemicals once they are on 
the market.228 
 Additionally, the definition section of TSCA specifically exempts 
pesticides from the definition of “chemical substance” and therefore 
from regulation under TSCA.229 Thus, EPA cannot regulate pesticides 
under TSCA, and pesticides are the only class of chemicals that EPA has 
                                                                                                                      
221 See Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 346a(p)(3)(A) (2006). 
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226 15 U.S.C. § 2605(c). 
227 Id. § 2605(a). 
228 Sachs, supra note 9, at 314–15. 
229 See 15 U.S.C. §§ 2602, 2605. 
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been mandated, rather than simply granted permission, to test under 
section 408(p) of the Federal Food Quality Protection Act.230 
 Therefore, at this stage of testing, TSCA is a largely inadequate tool 
to regulate endocrine disruptors because it is limited to regulating non-
pesticide chemicals, while EPA is only mandated to test pesticides.231 
However, if EPA expands testing to non-pesticide EDCs, they could po-
tentially be regulated under TSCA, with greater options for remedies 
than FIFRA’s single, extreme cancellation procedure.232 
C. Future Regulation of Endocrine Disruptors 
 Neither TSCA nor FIFRA offer perfect solutions to regulating en-
docrine disruptors.233 However, these statutes are the best available 
tools for regulating EDCs, and at least provide a possible avenue for 
post-testing regulation.234 Presuming that testing on EDCs shows the 
potential for human and environmental health harms, it is crucial for 
EPA to regulate EDCs to protect against these harms. Given the largely 
inadequate existing structures under TSCA and FIFRA, new testing 
data might provide the needed impetus for proposing new legislation 
to comprehensively monitor and minimize dangerous chemicals in this 
country. 
Conclusion 
 It is crucial that society has adequate information regarding the 
many chemicals that are present in our drinking water, food, contain-
ers, plastics, detergents, and more.235 Chemicals that individuals en-
counter and ingest in small doses every day could have potentially seri-
ous health consequences, both for current and future generations. 
EDCs can potentially cause infertility, immune disorders, metabolic 
disorders, and cancer.236 Without sufficient scientific data, EPA is un-
able to properly assess whether or not the chemicals that surround us 
on a daily basis pose an “unreasonable risk of harm to human health” 
                                                                                                                      
230 Pub. L. No. 104–170, 110 Stat. 1489 (codified as amended at 21 U.S.C. § 346a(p) 
(2006)). 
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235 Supra Part I.B. 
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and should therefore be regulated under laws such as FIFRA and 
TSCA.237 
 Congress took the first important step towards this regulation: 
Congress mandated that EPA must test all pesticide chemicals for their 
endocrine effects.238 It is everyone’s duty as active citizens to force EPA 
to fulfill these statutory obligations, and require that industry submit 
their pesticides to stringent new testing technologies.239 If EPA fails its 
mandate, the citizen suit provisions of the Administrative Procedure 
Act can serve as a tool to force the Agency to require up-to-date testing 
of pesticides.240 Additionally, once EPA fulfills its mandates, citizens 
should further advocate for the testing of all endocrine disruptors be-
yond just pesticides.241 Finally, citizens should not stop at testing, but 
should pressure EPA to appropriately regulate EDCs after testing is 
complete.242 
 
237 See Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 346a(p)(6)(2006); supra Part IV. 
238 See 21 U.S.C. §§ 346a(p)(1), (3)(A). 
239 See id.; supra Part II.E. 
240 See Administrative Procedure Act, 5 U.S.C. § 706 (2006). 
241 See supra Part II. 
242 See supra Part IV. 
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